This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Globus Medical's U.S. Spine Arm Grows, Product Launches Aid
by Zacks Equity Research
Globus Medical (GMED) is on course to commercially market ExcelsiusGPS platform and launch its spine deformity solution in early fourth quarter.
Globus Medical (GMED) Q3 Earnings Meet Mark, Revenue View Up
by Zacks Equity Research
Globus Medical (GMED) reports robust top-line numbers for the third quarter on segmental strength.
Globus Medical (GMED) Q3 Earnings Meet Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 0.00% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.
IART or GMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
IART vs. GMED: Which Stock Is the Better Value Option?
Globus Medical (GMED) Up 10.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IART or GMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
IART vs. GMED: Which Stock Is the Better Value Option?
Globus Medical (GMED) Q2 Earnings In Line, Revenue View Up
by Zacks Equity Research
Globus Medical's (GMED) spine business gains traction from solid worldwide growth in the second quarter.
Globus Medical (GMED) Q2 Earnings Match Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 0.00% and 5.77%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Globus Medical (GMED) Q2 Earnings Expected to Decline
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Down 13.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Globus Medical Reveals Positive Study Results for ExcelsiusGPS
by Zacks Equity Research
Results of the study of ExcelsiusGPS reached a milestone for Globus Medical (GMED) in the field of robotics-assisted, minimally invasive pedicle screw placement procedure
Globus Medical (GMED) Q1 Earnings Miss, Revenues Grow Y/Y (Revised)
by Zacks Equity Research
Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.
Globus Medical (GMED) Q1 Earnings Miss Mark, Margins Weak
by Zacks Equity Research
Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.
Globus Medical (GMED) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of -12.20% and -1.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Reports Next Week: What Awaits?
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical Global Base Solid, Pricing Scenario Bothers
by Zacks Equity Research
Globus Medical (GMED) is upbeat about its growth prospects in the current and the emerging global markets through a continual expansion of direct and distributor sales forces.
Globus Medical (GMED) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 7.50% and 0.22%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Surges: Stock Moves 7.1% Higher
by Zacks Equity Research
Globus Medical (GMED) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
New Strong Buy Stocks for December 20th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Globus Medical (GMED) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 18.18% and 1.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.